## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.1% below STRENGTH zone (3.0-6.0%); PEG 1.85 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($243.08)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Labcorp Holdings Inc. $LH Shares Sold by Wedge Capital Management L L P NC**
- Source: MarketBeat | 20251221T123520 | Somewhat-Bullish | Relevance: 100%
- Wedge Capital Management L.L.P. NC significantly reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 19.3% in the third quarter of 2025, selling 22,859 shares and retaining 95,783 shares valued at approximately $27.5 million. Concurrently, company insiders, including CEO Adam H. Schechter and Director Richelle P. Parham, also reduced their holdings. Despite these sales, Labcorp has received more positive sentiment from analysts, with several firms raising price targets, leading to an average "Moderate Buy" rating and a price target of $299.08.

**2. Assenagon Asset Management S.A. Trims Position in Labcorp Holdings Inc. $LH**
- Source: MarketBeat | 20251221T090834 | Somewhat-Bullish | Relevance: 96%
- Assenagon Asset Management S.A. significantly reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 69.8% in the third quarter, while company insiders also sold shares. Despite these sales, analyst sentiment remains largely positive, with a "Moderate Buy" rating and an average target price of $299.08. Labcorp has also announced a quarterly dividend and provided robust FY2025 earnings guidance.

**3. Backbone of Discovery: A Deep Dive into Charles River Laboratories (CRL)**
- Source: FinancialContent | 20251223T101000 | Neutral | Relevance: 61%
- Charles River Laboratories (CRL) is an indispensable backbone of the global pharmaceutical industry, participating in the development of over 80% of FDA-approved drugs in the last five years. After a tumultuous period, CRL is undergoing a strategic realignment with a $1 billion buyback program and a pivot towards AI-driven discovery, aiming to evolve into a high-tech drug development powerhouse. The company's business model spans Discovery and Safety Assessment, Research Models and Services, and Manufacturing Solutions, with its stock recovering in 2025 due to regulatory resolutions and a focus on shareholder returns.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.1% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.4M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.85 elevated, pricing in significant growth expectations. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.0B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.85 |
| Forward P/E | 14.4 |
| Current P/E | 15.5 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.0% to -3.1% (-4.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.98x), long-term trend not supportive. MACD histogram bearish (-0.86), momentum weakening. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.15% (CS: 16) | Weak |
| RSI_14 | 38.7 | Neutral |
| MACD Histogram | -0.86 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 0.957x | Below |
| vs SMA200 | 0.983x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $253.18
- **Stop Loss:** $243.08 (4.0% risk)
- **Target:** $263.28 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 118
- **Position Value:** $29,875.24
- **Portfolio %:** 29.88%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*